BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240429
DTEND;VALUE=DATE:20240503
DTSTAMP:20260515T203621
CREATED:20231124T115148Z
LAST-MODIFIED:20231124T115309Z
UID:38225-1714348800-1714694399@www.pharmajournalist.com
SUMMARY:3rd LNP Formulation & Process Development Summit
DESCRIPTION:Following the success of the first 2 years of the LNP Formulation & Process Development Summit\, we are hugely excited to announce the much-anticipated return of this world-leading summit in 2024. \nThis April\, the 3rd LNP Formulation & Process Development Summit returns to Boston\, bringing together over 400 experts in LNP Biology\, Chemistry\, Formulation\, Analytical Development\, Process Development\, Manufacturing and more. This is your ultimate platform for sharing insights\, learning new concepts and networking to propel more LNPs into the clinic in 2024. \nJoin the ever-growing community of LNP pioneers as they tackle the challenges associated with developing safe\, compliant and efficacious LNPs\, to treat a variety of disease indications at a variety of target organs. This starts with the in vitro discovery of LNPs through to the manufacturing processes\, with end-to-end synergy fundamental. \nHear from industry powerhouses Pfizer\, Moderna\, Alnylam and more\, as well as new companies to share their insights to this community including Capstan Therapeutics\, AbbVie\, Mana Bio\, Serina Therapeutics\, Karma Biotechnologies and more. \nWith an expanded content offering and a 4-track\, 4-day summit format\, we continue to be the most comprehensive\, premium LNP content available to industry. Part of this year’s content growth\, the addition of the ‘LNP IP & Commercial Partnerships Focus Day’ has evolved with the current industry trends to secure long standing partnership to demonstrate clinical results\, as well as gaining a further handle on the current IP and legal landscape. \nTo know more visit: https://ter.li/s96la3
URL:http://www.pharmajournalist.com/event/3rd-lnp-formulation-process-development-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240507
DTEND;VALUE=DATE:20240510
DTSTAMP:20260515T203621
CREATED:20240117T105624Z
LAST-MODIFIED:20240117T120808Z
UID:38511-1715040000-1715299199@www.pharmajournalist.com
SUMMARY:3rd Next Generation RNA Therapeutics Summit
DESCRIPTION:The field of next generation RNA therapeutics continues to progress towards clinical translation\, poised with investments and collaborations. Yet\, key challenges like sequence design\, purity\, stability\, safety and translatability into clinical settings continue to prevent their full therapeutic potential from being realized. \nReuniting everyone involved in next generation RNA therapeutic development\, from Scientists and Academics to C-Level Executives\, the 3rd Next Generation RNA Therapeutics Summit returns to cover the depth and breadth of next generation RNAs\, including circular RNA\, self-amplifying RNA\, and more. \nWhere: Hilton Boston Bay Back\, Boston\, Massachusetts \nWhen: May 7-9\, 2024 \nWebsite: https://ter.li/7sk7zz \n\n20+ brand new case studies from leading biopharma\, including Pfizer\, Strand Therapeutics\, and Laronde\nInvestment and collaboration fireside chat\n3 interactive workshops on targeted delivery\, purification challenges\, and enabling next generation RNA therapeutic production\nYour opportunity to share your work in the Scientific Poster Session\n\nWhat’s next:  \nDownload your copy of the brochure: https://ter.li/7sk7zz \nRegister your place: https://ter.li/5jyjfj
URL:http://www.pharmajournalist.com/event/3rd-next-generation-rna-therapeutics-summit/
LOCATION:Hilton Boston Bay Back\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240508
DTEND;VALUE=DATE:20240510
DTSTAMP:20260515T203621
CREATED:20240208T123641Z
LAST-MODIFIED:20240208T123712Z
UID:38645-1715126400-1715299199@www.pharmajournalist.com
SUMMARY:Injectable Drug Delivery Conference and Exhibition
DESCRIPTION:The Injectable Drug Delivery Conference returns this year with an unparalleled agenda dedicated to revolutionizing the pharmaceutical and biotechnological landscapes. This pivotal event focuses on cutting-edge advancements in drug-device co-development\, advanced therapeutic modalities\, and the sustainability of injectable drug delivery systems. \n \nWhy Attend? \n\nExplore how devices can be co-developed alongside drug products to foster a collaborative approach\, improving biocompatibility and effective toxicological testing.\nExpand your knowledge on design strategies for injectable delivery of advanced therapies\, including cell and gene therapies\, large molecule delivery\, and navigating the challenges of sub-zero device requirements.\nDive into focused presentations tailored to a technical device development and primary packaging audience\, covering vial material selection\, silicone layer thickness studies\, and the standardization of primary container formats.\nGain comprehensive insights into sustainable device materials\, from development and selection through to disposal.\nLearn from major device developers about streamlining product development and CMC practices for effective compliance post-NDA/MAA approval.\n\nWho Should Attend? \nThis conference is designed for scientists\, R&D professionals\, regulatory specialists\, and anyone at the forefront of drug delivery technology and pharmaceutical device development seeking to network with peers\, learn from industry leaders\, and stay ahead of the curve in injectable drug delivery innovations. \nAdditional Information: \nAttendees can expect to leave with actionable insights and strategies to apply within their own practices and organisations. This conference offers a unique opportunity to connect with like-minded professionals and pioneers in the field. \nRegister now to secure your spot at the forefront of injectable drug delivery innovation!
URL:http://www.pharmajournalist.com/event/injectable-drug-delivery-conference-and-exhibition/
LOCATION:Hilton London Kensington\, 179-199 Holland Park Ave\, London\, W11 4UL\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240515
DTEND;VALUE=DATE:20240517
DTSTAMP:20260515T203621
CREATED:20240208T131147Z
LAST-MODIFIED:20240208T131147Z
UID:38664-1715731200-1715903999@www.pharmajournalist.com
SUMMARY:GLP-1-Based Therapeutics Summit
DESCRIPTION:The GLP-1-Based Therapeutics Summit is the Ultimate Industry Forum for Developers of GLP-1-Based Therapeutics Across Different Indications \nThe GLP-1-Based Therapeutics Summit is a once-a-year event\, uniting 60+ industry experts to help advance more specialized\, durable\, and efficacious GLP-1s while investigating commercial opportunities to crystallize pipeline strategy and indication expansion. \nGrab your copy of the full agenda \nAmidst the resounding success of Novo’s SELECT trial\, the clinical trial landscape finds itself inundated with a surge of innovative GLP-1 treatments. Each passing week witnesses the unveiling of new multi-million-dollar investments\, propelling GLP-1 players to the forefront of pharmaceutical revenue growth. \nIf you are looking to differentiate your GLP-1 products\, forge new relationships with fellow GLP-1 developers\, or discover the newest innovations in improving the tolerability\, efficacy\, and durability of GLP-1s\, there has never been a more appropriate time to unite and navigate this rapidly evolving space at the GLP-1-Based Therapeutics Summit this May! \nKey Highlights: \nUnraveling Exciting Opportunities to Apply GLP-1 Receptor Agonists Across a Wide Range of Indications\nIncluding cardiovascular\, renal\, obstructive sleep apnea\, MASH\, and neurodegenerative diseases with Eli Lily\, D&D Pharmatech\, and Altimmune \nOptimizing the Efficacy of GLP-1-Based Therapeutics\nHear the newest innovations raising the benchmark for more successful weight loss with Diasome Pharmaceuticals and BioAge Labs \nDeveloping a Robust Commercial Strategy \nDifferentiate your GLP-1 products from your competitors\, to effectively target specific patient segments with Altimmune and Regor Therapeutics
URL:http://www.pharmajournalist.com/event/glp-1-based-therapeutics-summit/
LOCATION:Hilton Philadelphia City Avenue\, 4200 City Ave\, Philadelphia\, PA\, 19131\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240521
DTEND;VALUE=DATE:20240524
DTSTAMP:20260515T203621
CREATED:20240208T111843Z
LAST-MODIFIED:20240208T112145Z
UID:38632-1716249600-1716508799@www.pharmajournalist.com
SUMMARY:6th Annual Treg-Directed Therapies Summit
DESCRIPTION:Driving Next Gen Treg Stimulation for Autoimmunity\, Transplantation & Inflammation \nReturning to Boston for its 6th year\, the 6th Treg-Directed Therapies Summit stands as the singular industry forum shining a spotlight on the groundbreaking research and clinical advancements in CAR-Treg and IL2 mutein therapies. Witness the convergence of leading industry and academic experts as they unite to propel the clinical efficacy of Treg therapies to new heights. \nAs the pioneering and longest-tenured meeting dedicated to optimizing and manipulating Treg-based approaches\, this summit invites you to become part of a community at the forefront of innovation. Gain unparalleled insights into the latest developments driving specificity\, delve into novel cell product design\, and explore the engineering of CAR-Tregs to enhance cell stability and durability. \nDon’t miss this unique opportunity to stay ahead in the dynamic landscape of Treg therapies. Join us and contribute to the ongoing dialogue that shapes the future of cutting-edge medical advancements. \nTo know more visit: https://ter.li/gfpnb0
URL:http://www.pharmajournalist.com/event/6th-annual-treg-directed-therapies-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240522
DTEND;VALUE=DATE:20240525
DTSTAMP:20260515T203621
CREATED:20240103T113206Z
LAST-MODIFIED:20240103T113206Z
UID:38410-1716336000-1716595199@www.pharmajournalist.com
SUMMARY:5th Gene Therapy Analytical Development Europe Summit
DESCRIPTION:The 5th Gene Therapy Analytical Development Europe – What to Expect in 2024? \nIn the face of evolving regulatory guidelines and mounting scrutiny\, the 5th Gene Therapy Analytical Development Europe Summit will discuss ways you can apply contemporary analytical tools to guarantee the consistency\, quality\, and safety of your gene therapy products. \nJoin leading CMC\, regulatory\, QC\, analytical and process development experts to gain access to novel data and recent case studies by industry professionals from AstraZeneca\, the MHRA\, Novartis\, Sarepta Therapeutics\, Roche\, Sanofi\, and many more. \nEnjoy in-depth\, valuable networking opportunities with scientists and senior decision makers from small biotech through to large pharma – perfect for those looking to further industry relationships. \nTo know more visit: https://ter.li/vz0jr4
URL:http://www.pharmajournalist.com/event/5th-gene-therapy-analytical-development-europe-summit/
LOCATION:15Hatfields\, Chadwick Court\, London\, SE1 8DJ\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240529
DTEND;VALUE=DATE:20240601
DTSTAMP:20260515T203621
CREATED:20240117T112916Z
LAST-MODIFIED:20240119T121741Z
UID:38533-1716940800-1717199999@www.pharmajournalist.com
SUMMARY:4th Gene Therapy Patient Engagement Summit
DESCRIPTION:Patient engagement is a crucial responsibility of any gene therapy company if they’re serious about progressing safe\, effective\, and meaningful therapies to patients. The 4th Gene Therapy Patient Engagement Summit is returning in 2024\, sitting at the unique interface of patient engagement and gene therapy\, from embarking on first in-human trials through to commercial therapeutics. \nDelve into key challenges including engaging in R&D and managing expectations of gene therapies\, language and nomenclature used to educate on what gene therapies are and what it means to participate in a clinical trial\, outlining informed consent to support clinical trial enrollment\, and understanding the latest regulatory requirements to effectively demonstrate that these transformative therapies are meaningful to patients. \nJoin 80+ patient advocacy and engagement professionals from gene therapy companies and patient advocacy groups to gain actionable insights that you can immediately implement into your own gene therapy programs. Unite with the leading voices in this community to develop solutions to the challenges that are unique to the gene therapy space. \nTo learn more and discover the full agenda\, visit the official event website at genetherapy-patient-engagement.com
URL:http://www.pharmajournalist.com/event/4th-gene-therapy-patient-engagement-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR